Why the study?
The association between cardiovascular risk and novel biomarkers in patients with type 2 diabetes mellitus required investigation.
Do novel biomarkers (VCAM-1, VEGF) associate with higher cardiovascular risk scores in patients with Type 2 diabetes mellitus?
Do novel biomarkers (VCAM-1, VEGF) associate with higher cardiovascular risk scores in patients with Type 2 diabetes mellitus?
VCAM-1 and VEGF are independently associated with higher cardiovascular risk scores in patients with Type 2 diabetes, indicating subclinical endothelial dysfunction and potential utility in risk assessment.
Aim: To investigate the association between cardiovascular risk and biomarkers in patients with Type 2 diabetes (T2DM). Methods: Cross-sectional study, with evaluation of traditional and new biomarkers (serum FGF-23, Syndecan-1 [Sdc-1] and vascular cell adhesion molecule-1 [VCAM-1] and urinary VEGF and kidney injury molecule-1 [KIM-1]) and risk scores (Framingham-FRS and UK Prospective Diabetes Study [UKPDS]). Results: 128 diabetics were included, with predominance of high risk by FRS and low risk by UKPDS. There was an independent association of VCAM-1 and VEGF with higher risk by FRS-lipids and UKPDS. Conclusion: There was an independent association of VCAM-1 and VEGF with higher cardiovascular risk, showing a subclinical endothelial dysfunction in T2DM. The inclusion of novel biomarkers to risk scores may increase accuracy when assessing cardiovascular risk of diabetic individuals.
No takes yet. Share an insight, caveat, or question.
Néri et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: